In this issue:
Survival outcomes in the FIRST trial of up-front treatment for multiple myeloma
Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
Blood transfusion-related outcomes in daratumumab-treated patients with RRMM
Novel agent-based salvage autologous stem cell transplantation for RMM
Response comparison of MM and monoclonal gammopathy of undetermined significance
Prognostic value of antigen expression in MM
Cellular proliferation by multiplex immunohistochemistry identifies high-risk MM
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in RRMM
JAM-A as a prognostic factor and new therapeutic target in MM
A phase 1 and 2 study of filanesib alone and in combination with low-dose dexamethasone in RRMM
Please login below to download this issue (PDF)